Sfoglia per AUTORE
PATRIARCA F
Collezione AO Cuneo

  

Items : 10

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. in Blood cancer journal / Blood Cancer J. 2024 Aug 21;14(1):141. doi: 10.1038/s41408-024-01116-5.

2024
AO Cuneo
AOU Città della Salute di Torino

Iori AP; Bernasconi P; Corradini P; Russo D; Nagler A; Carella AM; Marotta G; Cerretti R; Rivela P; Terruzzi E; Saporiti G; Pane F; Patriarca F; Saccardi R; Musto P; Chiusolo P; Olivieri A; Milone G; Santarone S; Borghero C; Cavattoni IM; Busca A; Micò MC; Pavoni C; Grassi A; Cavallaro G; Castagna L; Mordini N; Oldani E; et alii...

Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.

2021
AO Cuneo

Zamagni E; Nanni C; Dozza L; Carlier T; Bailly C; Tacchetti P; Versari A; Chauvie S; Gallamini A; Gamberi B; Caillot D; Patriarca F; Macro M; Boccadoro M; Garderet L; Barbato S; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Cavo M; Bodet-Milin C; Moreau P; Kraeber-Bodéré F; Zamagni E; Nanni C; Dozza L; Carlier T; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. in The Lancet. Haematology / Lancet Haematol. 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X.

2019
AO Cuneo

Benedetti F; Heinzelmann M; Milone G; Benedetti E; Russo D; Sierra J; Ferra C; Sorasio R; Finke J; Guidi S; Cimminiello M; Carella AM; Sureda A; Herrera P; Bethge W; Messina G; Selleri C; Risitano AM; Nagler A; Zallio F; Patriarca F; Sessa M; Wolschke C; Solano C; Bonifazi F; Pastore D; Jurado M; Terruzzi E; Narni F; et alii...

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21

2018
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Ghedini P; Cavo M; Gamberi B; Gay F; Patriarca F; Gallamini A; Bellò M; Bertone E; Rensi M; Bianchi A; Chauvie S; Nanni C; Versari A; Zamagni E;

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. in Leukemia / Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.

2016
AO Cuneo
AOU Città della Salute di Torino

Bruno B; Boccadoro M; Passera R; Giaccone L; Palumbo A; Omedè P; Fanin R; Boccasavia V; Brunello L; Ghione P; Ferrando F; Guarona G; Cena S; Benedetto R; Mordini N; Patriarca F; Festuccia M; Drandi D; Ferrero S; Ladetto M;

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.

2016
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Gamberi B; Cavo M; Gay F; Patriarca F; Gallamini A; Rambaldi I; Rensi M; Bellò M; Bianchi A; Versari A; Chauvie S; Zamagni E; Nanni C;

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. in The New England journal of medicine / N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.

2016
AO Cuneo

Kröger N; Solano C; Wolschke C; Bandini G; Patriarca F; Pini M; Nagler A; Selleri C; Risitano A; Messina G; Bethge W; Pérez de Oteiza J; Duarte R; Carella AM; Cimminiello M; Guidi S; Finke J; Mordini N; Ferra C; Sierra J; Russo D; Petrini M; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; et alii...

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. in Leukemia / Leukemia. 2014 Sep;28(9):1885-91. doi: 10.1038/leu.2014.79. Epub 2014 Feb 20.

2014
AO Cuneo

Corradini P; Vitolo U; Rambaldi A; Miceli R; Patriarca F; Gallamini A; Olivieri A; Benedetti F; Todeschini G; Rossi G; Salvi F; Bruno B; Baldini L; Ferreri A; Patti C; Tarella C; Pileri S; Dodero A;